Erschienen in:
31.01.2019 | ASO Author Reflections
ASO Author Reflections: Oncotype DX RS Complementing the Prognostic Stage in the Updated AJCC 8th Edition for T1-2N1M0 ER-Positive HER2-Negative Breast Cancer
verfasst von:
Maoli Wang, MS, Kejin Wu, MD, Hongliang Chen, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 5/2019
Einloggen, um Zugang zu erhalten
Excerpt
The breast cancer staging system used to be based on anatomic factors. Then the molecular subtype based on the validation of biologic markers was introduced to describe the prognosis and treatment benefit.
1 The prognostic stage system in the American Joint Committee on Cancer (AJCC) 8th edition for the first time incorporated nearly all the important biologic factors together with anatomic tumor-node-metastasis (TNM) factors. It would be the most accurate predictor of outcome in case of discordance between tumor burden and biology. In this era of precise medicine, clinical and genetic risks should be equally considered. Oncotype DX is the only multigene assay available to improve the classification of the prognostic stage. Cases with T
1-2N
0M
0 estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative cancer and RS lower than 11 should be categorized as pathologic prognostic stage IA. However, the significance of RS has not yet been fully evaluated for lymph node (LN)-positive cases.
2–4 This study aimed to evaluate the prognostic significance of Oncotype DX RS in T
1-2N
1M
0 ER-positive HER2-negative breast cancer based on the pathological prognostic stage using the Surveillance, Epidemiology, and End Results (SEER) database. …
